The patent litigation group at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. maintains a strong position in the life sciences sector, representing market leaders in federal district courts and administrative tribunals. It also acts as IP defense counsel, advising blue-chip companies like Eli Lilly on litigation strategy and navigating patent risks. Boston-based Michael Renaud, a prominent IP strategist, co-chairs the practice group with Thomas Wintner, recognised for his strong trial performance and extensive technical knowledge. In 2025, the firm underwent major changes, welcoming Daniel Brownstone from Fenwick & West LLP. Christina Sperry, Frank Gerratana and Pedro Suarez have left the firm.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Sector knowledge
Key clients
- Allogene
- Amgen
- ARS Pharmaceuticasl
- Collision Communications
- Copan Italia SpA
- Eikon Therapeutics
- Eli Lilly
- Glycosyn LLC
- JUUL Labs, Inc.
- Media Content Protection
- Mullen Industries
- Sanofi / SK bioscience
Work highlights
Represented Amgen in major BPCIA litigation to protect Prolia and XGEVA from biosimilar competition, securing key settlements and leading cases across multiple federal courts and international jurisdictions.
Mintz represented Media Content Protection (MCP) and Philips in a patent infringement case involving content protection technology against Intel, Dell, HP, and Lenovo.
Led in high-stakes patent litigation for JUUL Labs in the electronic nicotine delivery systems (ENDS) sector, combining offensive and defensive strategies before the ITC and U.S. District Court.
Practice head
Michael Renaud; Thomas Wintner
Other key lawyers
Daniel Brownstone